Front Oncol: Cisplatin combined with irinotecan for first-line treatment of metastatic or unresectable thymic carcinoma

Platinum-based chemotherapy is the standard treatment for metastatic or unresectable thymic cancer
.

However, the optimal chemotherapy regimen has not been determined, including whether it should be used in combination with second-line or more standard antineoplastic drugs

Platinum-based chemotherapy is the standard treatment for metastatic or unresectable thymic cancer

The primary endpoint of the study was ORR
.

Secondary endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and toxicity (adverse events)

The primary endpoint of the study was ORR

Eighteen patients with previously untreated metastatic/unresectable thymic carcinoma received irinotecan and cisplatin

Combination therapy resulted in an ORR of 44% and a DCR of 89%, of which 8 (44%) achieved PR and 8 (44%) were SD

Efficacy assessment

 Efficacy assessment

The median follow-up time was 29.
5 months, and the median progression-free survival (PFS) was 8.
4 months [95% CI: 2.
7-11.
6 months]
.

The median OS was 45.

The median follow-up time was 29.

PFS and OS

PFS and OS

Fifteen patients received S-1 as a second- or later-line regimen, with an ORR of 33% and a median progression-free survival of 8.
1 months (95% CI: 0.
7-10.
3 months)
.

Eight patients received carboplatin and paclitaxel as second- or later-line regimens with an ORR of 38% and a median progression-free survival of 4.

Fifteen patients received S-1 as a second- or later-line regimen, with an ORR of 33% and a median progression-free survival of 8.

         Efficacy of second- or later-line therapy

Efficacy of second- or later-line therapy

Grade 3 hematological toxicity occurred in 6 patients
.

The main treatment-related adverse events were nausea (73%), neutropenia (72%), and leukopenia (45%)

Grade 3 hematological toxicity occurred in 6 patients
.
The main treatment-related adverse events were nausea (73%), neutropenia (72%), and leukopenia (45%)
.
Three patients had grade 3 neutropenia; however, none of the patients had febrile neutropenia
.
Five patients experienced grade 3 non-hematologic adverse events, and one patient experienced grade 3 diarrhea
.
No patients experienced grade 4 adverse events and no treatment-related deaths
.
Cisplatin and irinotecan were discontinued in 3 patients due to gastrointestinal adverse events
.

             AEs

AEs

In conclusion, the study shows that cisplatin combined with irinotecan as a first-line chemotherapy regimen for metastatic thymic carcinoma has significant efficacy and acceptable toxicity
.

In conclusion, the study shows that cisplatin combined with irinotecan as a first-line chemotherapy regimen for metastatic thymic carcinoma has significant efficacy and acceptable toxicity
.
Studies have shown that cisplatin combined with irinotecan as a first-line chemotherapy regimen for metastatic thymic carcinoma has significant efficacy and acceptable toxicity
.
Studies have shown that cisplatin combined with irinotecan as a first-line chemotherapy regimen for metastatic thymic carcinoma has significant efficacy and acceptable toxicity
.

Original source:

Original source:

Fukuda A, Okuma Y, Hakosaki T, Mirokuji K, Yomota M, Hishima T and Hosomi Y (2022) Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis.
Front.
Oncol.
11:779700.
doi : 10.
3389/fonc.
2021.
779700

Fukuda A, Okuma Y, Hakosaki T, Mirokuji K, Yomota M, Hishima T and Hosomi Y (2022) Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis.
Front.
Oncol.
11:779700.
doi : 10.
3389/fonc.
2021.
779700 Leave a message here